



Instructions For Use

Valid as of 03.11.2022

For Research Use Only!

Medizym® anti-GAD M

REF 35071

Enzyme immunoassay for the determination of antibodies against Glutamic Acid Decarboxylase (GAD₆₅) in human serum



Mediphan GmbH
Ludwig-Erhard-Ring 3
15827 Blankenfelde-Mahlow OT Dahlewitz
Germany

Phone: +49 33708 4417 0
Fax: +49 33708 4417 25

info@medipan.de
www.medipan.de

RUO



1 Intended Purpose

The Medizym® anti-GAD M is a quantitative immunoassay for the determination of antibodies against Glutamic Acid Decarboxylase (GAD₆₅) in human serum.

The immunoassay is designed for research use only.

2 Relevance

Type 1 diabetes mellitus, also called insulin-dependent diabetes mellitus, is a chronic autoimmune disease caused by the selective destruction of the insulin-producing pancreatic beta cells. In this process, autoantibodies are formed against the substances and structures localised inside the beta cell, which indicate the cell damage.

The enzyme glutamic acid decarboxylase (GAD) catalyses the synthesis of the neurotransmitter GABA in the brain and beta cells. In humans, two isoenzymes of GAD are known: GAD65 with a molecular weight of 65 kD and GAD67 with 67 kD. The autoimmune reaction in type 1 diabetes is always directed against GAD65. These diabetes-specific autoantibodies react mainly with spatial epitopes of GAD65.

3 Test Principle

The ELISA (Enzyme Linked Immunosorbent Assay) is an immunoassay for the determination of specific antibodies. The strips of the microtiter plate are coated with test-specific antigens. If antibodies are present in the sample, they bind to the antigens. A second biotinylated antigen binds the immobilized antibody. The assay utilizes the ability of antibodies to act bivalently with immobilized and soluble antigens. Streptavidin conjugated with

the enzyme peroxidase detects the generated immune complex. A colorless substrate is converted into the colored product by the peroxidase. The signal intensity of the reaction product is proportional to the antibody activity in the sample. After stopping the signal intensity of the reaction product is measured photometrically.

4 Test Components

Component	Description
Microtiter plate A MP 1 piece	12 breakable microtiter strips (ready-to-use), 8 wells per strip, each well coated with recombinant human GAD ₆₅
Calibrator 0 – 5 CAL 6 x 1.0 mL	Colored dilutions of human serum (ready-to-use; contains ProClin 950) The antibody activities are indicated on the quality control certificate.
Positive control CII CONTROL + 1 x 1.0 mL	Colored dilution of human serum (ready-to-use; contains ProClin 950) The antibody activity is indicated on the quality control certificate.
Sample diluent C DIL 1 x 20 mL	Colored solution (ready-to-use; contains ProClin 950)
GAD₆₅-Biotin H START 1 x 0.2 mL	Concentrated start reagent biotinylated GAD ₆₅ (contains sodium azide)
Diluent for GAD₆₅-Biotin J BUF H 1 x 20 mL	Colored solution (ready-to-use; contains ProClin 950)
Streptavidin-peroxidase (SA-POD) D CONJ 1 x 0.2 mL	Concentrated streptavidin conjugated to horseradish peroxidase (100x)
Diluent for SA-POD G BUF D 1 x 20 mL	Solution (ready-to-use; contains ProClin 950)
Wash buffer B WASHB 1 x 100 mL	Concentrated solution (10x; contains ProClin 950)
Substrate E SUB 1 x 15 mL	3,3',5,5'-Tetramethylbenzidine (ready-to-use)
Stop solution F STOP 1 x 15 mL	0.25 M Sulfuric acid (ready-to-use)
Adhesive Foil 2 pieces	-
QC Certificate 1 piece	-
Instructions for Use 1 piece	-

5 Materials required but not provided

- Common laboratory equipment
- Precision pipettes (5 – 1000 µL), multi-channel pipettes (100 – 1000 µL) and disposable pipette tips
- Graduated cylinders (100 – 1000 mL)
- Vortex mixer or other rotators
- Microtiter plate shaker
- Microtiter plate washer or wash comb

- Microtiter plate reader with optical filters for 450 nm and 620 nm or 690 nm
- Adsorbent paper or paper towel
- Distilled or de-ionized water

6 Storage and Stability

Upon receipt, all test components must be stored at 2 °C to 8 °C, preferably in the original kit box. If stored properly in their original containers, all components are stable until their expiry date.

7 General Information

This product is for research use only. The instructions for use must be carefully read before use. They are valid only for the present product with the given composition and must be strictly followed to ensure reliable test results. Deviations can lead to erroneous test results. Components must not be exchanged by test reagents of different lots or of other manufacturers.

Contamination of reagents must be avoided by use of aseptic techniques when removing aliquots from the vials. After use, reagent vials must be tightly closed with their corresponding caps. Cross-contamination of samples or reagents can lead to inconsistent test results and must be avoided by use of consistent pipetting techniques.

Exposure of reagents to strong light must be avoided throughout the entire test procedure and storage.

Insufficient washing will result in poor precision and elevated measurement signals. After each washing step any residual fluid has to be removed completely.

8 Preparation

8.1 Preparation of Reagents

All components including the microtiter plate must be brought to room temperature (RT: 18 °C to 25 °C) before use for at least 30 min. All liquid components must be mixed gently to ensure homogeneity.

8.1.1 Microtiter Plate

The microtiter plate is sealed in an aluminium bag. Unused test strips should always be stored refrigerated and protected from moisture with the desiccant in the properly sealed aluminum bag. Carefully resealed, the test strips can be used for 8 weeks after opening.

8.1.2 Calibrators

The calibrators are ready-to-use and must not be diluted any further. Calibrators must be used in each test run.

8.1.3 Controls

The positive and the negative controls are ready-to-use and must not be diluted any further. Controls must be used in each test run. Laboratories can also validate their own control samples and use them alternatively.

8.1.4 GAD₆₅-Biotin (H) and Diluent (J)

A sufficient amount of GAD₆₅-Biotin solution must be prepared by diluting x mL GAD₆₅-Biotin (H) with y mL diluent for GAD₆₅-Biotin (J) directly before use. For exact dilution volumes x and y see certificate of analysis supplied with the kit. The dilution ratio for manual and automated processing can be different. The GAD₆₅-Biotin solution prepared is to be used within one day and must not be stored.

8.1.5 Streptavidin-peroxidase (D) and Diluent (G)

A sufficient amount of streptavidin-peroxidase solution must be prepared by diluting SA-POD concentrate (D) 1 + 99 (e. g. 0.1 mL SA-POD concentrate with 9.9 mL diluent for SA-POD (G)). The SA-POD solution prepared is stable up to 4 weeks at 2 °C to 8 °C.

8.1.6 Wash Buffer

The wash buffer is concentrated and must be diluted 1:10 with distilled water before use (e. g. 100 mL + 900 mL). A sufficient

amount of washing solution must be prepared. The diluted washing solution can be stored at 2 °C to 8 °C up to 30 days.

8.1.7 Substrate

The substrate is ready-to-use. Exposure of the substrate solution to strong light should be avoided.

8.1.8 Stop Solution

The stop solution is ready-to-use.

8.2 Preparation of Samples

8.2.1 Sample Material

The use of freshly collected serum from blood taken by venipuncture is recommended. The use of icteric, lipemic, hemolytic or bacterially contaminated samples should be avoided. Insoluble substances must be removed from the sample by centrifugation. Samples must not be thermally inactivated.

8.2.2 Sample Storage

Samples may be kept at 2 °C to 8 °C up to three days. Long-term storage requires -20 °C. Repeated freezing and thawing should be avoided. For multiple use, samples should be aliquoted and kept at -20 °C.

9 Test Performance

9.1 Pipetting Scheme

The following pipetting scheme is recommended:

	1	2	3	4
A	CAL 0	Sample 2		
B	CAL 1	Sample 3		
C	CAL 2	Sample 4		
D	CAL 3	Sample 5		
E	CAL 4	...		
F	CAL 5	...		
G	CII	...		
H	Sample 1	...		

9.2 Procedure

The indicated incubation times and temperatures must be adhered to and significant time shifts during pipetting samples and reagents must be avoided. The microtiter plate should be shortly shaken after addition of reagents.

Step	Description
1. Addition of dilution buffer	Add 100 µL ready-to-use dilution buffer into the wells of samples; leave the wells of calibrators and controls empty.
2. Addition of calibrators, controls and samples	Add 50 µL ready-to-use calibrators, controls and undiluted samples per well
3. Incubation	Cover the plate and incubate for 60 min. at RT while shaking at 500 rpm on a plate shaker
4. Preparation of reagents	Prepare sufficient volumes of reagents (B, D/G, H/J)
5. Wash cycle	Aspirate the solution and wash 3 times with 300 µL washing solution with at least 5 seconds soaking time each; dry by tapping the microtiter plate on a paper towel to remove any residual droplets
6. Addition of start reagent	Add 100 µL of diluted GAD ₆₅ -Biotin solution (prepared from H and J) to each well

7. Incubation	Cover the plate and incubate for 60 min. at RT while shaking at 500 rpm on a plate shaker
8. Wash cycle	Aspirate the solution and wash 3 times with 300 µL washing solution with at least 5 seconds soaking time each; dry by tapping the microtiter plate on a paper towel to remove any residual droplets
9. Addition of conjugate	Add 100 µL of diluted SA-POD (prepared from D and G) to each well
10. Incubation	Cover the plate and incubate for 20 min. at RT while shaking at 500 rpm on a plate shaker
11. Wash cycle	Aspirate the solution and wash 3 times with 300 µL washing solution with at least 5 seconds soaking time each; dry by tapping the microtiter plate on a paper towel to remove any residual droplets
12. Addition of substrate	Add 100 µL ready-to-use substrate to each well and shake the plate shortly
13. Incubation	Cover the plate and incubate for 20 min. in the dark at RT without shaking
14. Addition of Stop Solution	Add 100 µL ready-to-use stop solution to each well and shake the plate shortly
15. Analysis	Read optical density (OD) at 450 nm versus 620 or 690 nm within 30 min. after stopping the reaction

9.3 Automation

Automated processing of the immunoassays must be performed analogous to manual use and validated by the user.

10 Test Evaluation

10.1 Metrological Traceability

The immunoassay is calibrated using the international WHO reference preparation NIBSC code 97/550. Quantitative results are expressed in IU/mL.

10.2 Quantitative Evaluation

For generation of a standard curve, the optical signals (optical density, OD) of the calibrators are plotted against their antibody activities and correlated by a 4-parameter logistic (4 PL) fit. Antibody activities of unknown samples can be derived directly from their optical signals by use of the generated standard curve.

10.3 Criteria of Validity

Test runs are only valid if the following criteria of validity are fulfilled:

- OD CAL 0 < CAL 1 < CAL 2 < CAL 3 < CAL 4 < CAL 5
- OD CAL 5 > 1.2
- The negative control must be evaluated negative.
- The positive control must be evaluated positive and present an antibody activity within the validity range indicated on the quality control certificate.

If these criteria are not met, the test is not valid and must be repeated.

10.4 Troubleshooting

In case of an invalid test run, the expiry dates and storage conditions, incubation times and temperatures, and precise calibration of all instruments used should be verified. If no reason for an invalid test run could be identified, please contact the supplier or manufacturer of the product.

10.5 Reference Ranges

The reference ranges are indicated below:

	Interpretation
Antibody activity < 5 IU/mL	negative
Antibody activity ≥ 5 IU/mL	positive

As a result of different seroprevalences in individual regions, each laboratory should verify the reference ranges by own analysis and adapt, if necessary.

10.6 Interpretation of Test Results

A positive test result indicates the presence of specific antibodies. A negative result indicates the absence of specific antibodies, but does not exclude the possibility of an autoimmune reaction. In case of a borderline test result, a reliable evaluation is not possible.

10.7 Limitations of the Method

For research use only. Not for use in diagnostic procedures.

11 Performance Characteristics

11.1 Analytical Performance Characteristics

11.1.1 Analytical Sensitivity and Specificity

The Limit of Blank (LoB) was determined by multiple analysis of sample diluent. The Limit of Quantitation (LoQ) was correlated to an interassay coefficient of variation of 20 %.

	Analytical Sensitivity
Limit of Blank (LoB)	< 0.5 IU/mL
Limit of Quantitation (LoQ)	< 1.0 IU/mL

11.1.2 Precision

The precision of test results was assessed by the determination of the intra- and interassay variation by the analysis of multiple samples with different antibody activities.

	Intraassay Precision		Interassay Precision	
	IU/mL	CV (%)	IU/mL	CV (%)
Sample 1	17	9,0	15	9.1
Sample 2	80	6.1	76	5.5
Sample 3	183	5.7	186	5.3

11.1.3 Measurement Range

Reliable accuracy, trueness, precision, linearity and recovery of test results have been observed within the measurement range of the assay from the LoQ to the upper calibrator in comprehensive studies. Samples with test results above the upper calibrator should be reported as >max. Samples with test results below the LoQ should be reported as <min. If test results above the upper calibrator are observed, the samples may be tested at a higher dilution. The resulting antibody activity must be multiplied with the additional dilution factor.

12 Warnings and Precautions

The product is designed exclusively for research use by qualified, authorized and trained personnel. All test components and human samples should be handled with care as potentially hazardous. Good laboratory practices (GLP) and all relevant regulations should be adhered to.

In case the product is damaged or product information including labelling is wrong or incorrect, please contact the manufacturer or supplier.

This product contains preparations of human and / or animal origin. Any material derived from human body fluids or organs used for the preparation of components were tested and found negative for HBsAg (Hepatitis B-Virus-surface Antigen) and anti-

HIV as well as anti-HCV antibodies. However, all components and all samples should be handled as potentially hazardous in accordance with national laws and appropriate guidelines on biological safety.

As the product contains potentially hazardous materials, the following precautions should be followed: Do not smoke, eat or drink while handling kit material or samples. Avoid direct contact to kit material or samples by wearing protective gloves laboratory coat and safety glasses. Never pipette material by mouth. Wipe up spills promptly and wash the affected surface thoroughly with a decontaminant. Wash hands thoroughly after use.

Some of the reagents contain ProClin (< 1.0 %) as a preservative, may cause skin sensitization (H317) and must not be swallowed or allowed to come into contact with skin or mucosa (P280, P333+P313).

Some of the reagents contain sodium azide (< 0.1 %) as a preservative and must not be swallowed or allowed to come into contact with skin or mucosa. The possible formation of heavy metal azides in the drainage has to be prevented by sufficient rinsing with water.

The information in the safety data sheet on possible hazards, first aid measures, measures in the event of the unintentional release of large quantities, handling and storage, personal protective equipment, information on disposal as well as information on toxicology must be observed.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the member state in which the user and/or the subject is established.

13 Disposal

For decontamination and disposal the recommendations of the CDC as well as the relevant local and national environmental guidelines and regulations should be adhered to. Samples, potentially contaminated materials and infectious waste must be decontaminated, e.g. by autoclaving for 20 min. at 121 °C.

14 References

- Batstra MR, Anstoot HJ, Herbrink P: Prediction and diagnosis of type 1 diabetes using β -cell autoantibodies. Clin. Lab. 2001, 47, 497 – 507.
- Seissler J, Hatzigelaki E, Scherbaum WA: Modern concepts for the prediction of type 1 diabetes. Exp. Clin. Endocrinol. Diabetes 2001, 109, Suppl 2, 304 – 16.
- Pozzilli P, Manfredi S, Monetini L: Biochemical markers of type 1 diabetes, clinical use. Scand. J. Clin. Lab. Invest. Suppl. 2001; 235, 38 – 44.
- Schernthaner G, Hink S, Kopp HP et al.: Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1.5 diabetes). Exp. Clin. Endocrinol. Diabetes. 2001, 109, Suppl 2, 94 – 108.
- Winter WE, Harris N, Schatz D: Immunological markers in the diagnosis and prediction of autoimmune Type 1a diabetes. Clinical Diabetes 2002, 20, 183 – 91.

15 Symbols

	Manufacturer
	For research use only
	Catalogue number
	Batch code
	Temperature limit
	Use-by date
	Consult instructions for use
	Contains sufficient for <n> tests
	Do not re-use
	Caution
	Warning
	Biological risk
	Keep away from sunlight
	Microtiter plate
	Calibrators
	Negative control
	Positive control
	Enhancer
	Start reagent
	Diluent for start reagent
	Conjugate
	Diluent for conjugate
	Wash buffer
	Substrate
	Stop solution

16 Changes

Changes in current Instructions for Use	
Current Version	001/11.2022
Summary of Changes	Initial version